Explore Our Network

Aridica Corporation is dedicated to advancing immune system research and clinical applications by providing high-quality, automated immune cell isolation solutions. Their mission is to accelerate the development of diagnostics and next-generation therapeutics by simplifying and standardizing the process of immune cell separation. With a focus on automation, reliability, scalability, and sustainability, Aridica aims to empower researchers and clinicians to unlock the full potential of the immune system for improved health outcomes.

ARMR Sciences, Inc. is a biotechnology company dedicated to ending the fentanyl crisis and defending against synthetic drug threats through American innovation. The company is pioneering scalable, preventative immunotherapies to protect individuals before exposure to lethal synthetic drugs like fentanyl, moving beyond reactive treatments to address the root causes of overdose deaths. ARMR's technology is supported by foundational licenses from the Department of Defense and aligns with federal health and defense agencies. The multidisciplinary team brings significant experience from leading institutions and companies such as MindMed, iBio, Ridgeback Biotherapeutics, Scripps Research, Boston Children’s Hospital, Harvard Medical School, and more. United in their vision to save lives, ARMR is committed to providing lasting protection and solving the overdose crisis for millions in need.

Astrapi Corporation is a leader in revolutionary communication methods, specifically through spiral-based modulation. One capability is the Astrapi Spectrum Analyzer which enables an extremely precise method to measure continuously varying signal power which includes brain waves. This innovative technology is set to transform the next generation of communications by enhancing spectral efficiency and providing new ways to combat channel impairments. Astrapi's technology supports performance advances across various communications networks, including cellular, satellite, and defense communications, among others. Important medical applications of the Astrapi Spectrum Analyzer may include: 1. brain disorder diagnostics and measurement; 2. tumor localization; 3. enhanced prosthetics; and 4. brain-computer interfaces. Astrapi is in the process of spinning out a medical company to focus specifically on the medical applications of its Spectrum Analyzer. We welcome investors and collaborators. Our business model is to license to companies already in the medical field.

Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is advancing to Phase 2 clinical trials.

Berkeley FIT is dedicated to fostering innovation through technology, specializing in AI, software engineering, and digital product design. The company partners with both industry leaders and startups to solve complex challenges, leveraging expertise in modern software development, cloud platforms, AI & machine learning, and user-centered UX/UI design. Their mission is to bridge the gap between current needs and future possibilities by delivering technology-driven solutions with real-world impact.

Biobeat is a global leader in wearable remote patient monitoring technology, revolutionizing hypertension diagnosis and management through innovative, non-invasive, cuff-less blood pressure monitoring systems. Their mission is to ensure all hypertension patients are monitored and managed effectively, empowering healthcare providers with accurate, real-time data to optimize patient care. Biobeat leverages proprietary patented PPG sensor technology and advanced data analytics to deliver continuous, medical-grade monitoring solutions that enhance clinical decision-making, improve patient compliance, and enable proactive interventions. With FDA-cleared and CE-certified devices, Biobeat is committed to transforming healthcare delivery, supporting both in-hospital and home-based care, and driving better patient outcomes worldwide.

Cambridge Medical Technologies (CMT) is pioneering a transformative leap in combat casualty and critical care medicine with its advanced biosensor platform. Originally founded on research funded by DARPA, the Army Research Office (ARO), and Walter Reed Army Institute of Research, CMT’s mission has been clear from the start: develop non-invasive, real-time monitoring of blood chemistry for soldiers in the field. Their breakthrough technology samples subcutaneous interstitial fluid (ISF) painlessly and analyzes it outside the body for key biomarkers—starting with glucose and lactate, and now expanding to include blood pH. This innovation is especially critical in military medicine, where early detection of hemorrhagic shock, sepsis, and metabolic failure can mean the difference between life and death. Traditional vital signs like heart rate and blood pressure often fail to reveal the severity of internal injuries or compensated shock. CMT’s biosensor platform fills this gap by continuously tracking biochemical indicators that reflect tissue perfusion (lactate), acid-base status (pH/base deficit), and stress response (glucose). These metrics are widely recognized in both civilian and military clinical guidelines as essential for guiding resuscitation and predicting outcomes. Unlike conventional blood tests that require invasive sampling and lab processing, CMT’s devices—such as the LabPatch and LabClasp—use a proprietary method to extract ISF through the skin without needles. Within seconds, they deliver accurate readings of lactate and glucose, with pH integration underway. This allows medics and clinicians to monitor trends in real time, enabling faster, more informed decisions during trauma care, sepsis management, and evacuation triage. For combat medics operating in austere environments, this technology is a game-changer. A wearable patch could continuously stream vital biochemical data from a wounded soldier to a handheld device, alerting caregivers to rising lactate or falling pH before traditional signs deteriorate. In emergency departments and ICUs, the same platform could reduce reliance on repeated blood draws, improve response times, and enhance patient outcomes. CMT’s work aligns directly with the goals of the Department of Defense’s Advanced Medical Monitor (AMM) initiative under the Medical Technology Enterprise Consortium (MTEC). As future combat operations are expected to produce mass casualties and strain medical resources, integrating biochemical monitoring into standard vital sign systems is no longer optional—it’s urgent. CMT’s technology offers a scalable, field-ready solution that brings ICU-level insight to the point of injury. In summary, CMT is redefining how we monitor and manage shock and sepsis in both military and civilian care. By combining non-invasive ISF sampling with rapid, multi-analyte analysis, their platform empowers caregivers with the data they need—when and where they need it most.

Celestial Therapeutics is a Johnson & Johnson Innovations-JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.

Cellphire Therapeutics' vision is that no-one should die from controllable hemorrhage. In the US, hemorrhage remains a leading cause of preventable death for those under 45. For this reason, we need new products with improved hemostatic efficacy and ensure they are in the hands of clinicians when they are needed. The extremely short shelf-life – 7 days max – of platelets used as the standard of care Liquid Stored Platelets (LSP) gives rise to an inability to create an inventory buffer to address any increase in demand, particularly mass casualty events, military conflicts or significant hemorrhage situations such as post-partum hemorrhage and traumatic injury. This means: 1) Platelet rationing occurs across the system. 2) Nearly 400,000 platelet units a year expire before they can get to a patient in need. 3) Ten million Americans on anti-platelet or anticoagulant medications face greater risks when effective therapies aren’t available to clinicians, complicating surgery and trauma care.

ClotProtect Therapeutics Limited is a UK-based therapeutics spin-out from the University of Leeds, pioneering a first-in-class small molecule anti-fibrinolytic to address acute bleeding. The company is led by a team of world-leading scientific experts, clinical key opinion leaders, and experienced pharma industry professionals. Their mission is to transform the treatment of acute haemorrhage and traumatic bleeding, aiming to save lives with innovative, more effective therapies. ClotProtect is currently in preclinical development, working towards identifying a clinical drug candidate that offers superior efficacy and safety compared to current standards of care.

CMTx Biotech, Inc. is an emerging biopharmaceutical company working to develop and commercialize host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Our lead drug candidate is a clinically-tested, highly-stable, orally-administered small molecule that has been shown to improve survival and prevent lung injury in a wide variety of animal models of sepsis, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) across several species, including mice, rats, hamsters, pigs and sheep. Having already secured approximately $4M in funding to-date, including $3.6M in NIH SBIR/STTR grants, we are actively seeking non-dilutive funding, private investment capital and/or an established strategic partner to help advance human clinical trials and FDA Animal Rule development, as well as to expand our product pipeline.

Cohesys is a clinical-stage company focused on innovating fracture repair solutions. Its product, BoneTape, is the first bone fixation device that does not require drilling into healthy bone. The company aims to disrupt the traditional surgical-repair industry that relies on invasive plates and screws.

Crainio is a UK-based medical technology company focused on revolutionizing the measurement of intracranial pressure (ICP) through a non-invasive, real-time, and affordable device. Their mission is to improve the diagnosis and treatment of traumatic brain injury (TBI) by providing clinicians with continuous ICP monitoring without the need for invasive procedures. Using low-power infrared light and advanced machine learning algorithms, Crainio's technology aims to make ICP measurement accessible, safe, and effective for a wide range of healthcare settings.

CranioSense, Inc. is a clinical stage company focused on revolutionizing the measurement of intracranial pressure (ICP) with their innovative IPASS technology. This non-invasive solution aims to provide rapid and safe ICP assessments, addressing the critical need for better management of traumatic brain injury (TBI) and other conditions associated with elevated cranial pressure. By eliminating the need for invasive procedures, CranioSense is poised to significantly improve patient outcomes and healthcare practices.

DANE Health, Inc. created an Agentic Medical AI assistant, initially concentrating on neurology and triage to revolutionize care pathways. The company provides individuals and healthcare professionals with practical insights, tailored support, and professional reports, all while ensuring privacy and security. Our AI agent engages in lifelike conversations to tackle complex management or recovery challenges, while monitoring progress over time. DANE Health aims to supply clinicians with clear data to improve patient care and aid in better recovery.

FiteBac Technology/FiteBac Pharma's innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21. FiteBac K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction.

Frontier Bio creates lab-grown human tissues to reduce the worldwide organ shortage. Their first clinical product is a tissue-engineered vascular graft made from the patient's own cells.

Gateway Biotechnology is dedicated to developing first-in-class drug therapies for tinnitus and hearing disorders. Founded in 2011 by Drs. Jianxin Bao, Rick Chole, and Philip Perez, the company aims to translate basic scientific discoveries into novel therapies. With a focus on addressing the unmet needs of tinnitus patients, Gateway Biotechnology is advancing innovative solutions like GW-TT2 and GW-TT5 to provide effective treatments for this debilitating condition.

GreenLifeTech is dedicated to improving sustainability by extending the shelf life of fresh produce, thereby reducing food waste and promoting healthier living. In addition, the technology is applicable to preserving transfusion blood. Their initial innovative product, FreshDefend™, is a smart countertop system that can extend the life of fruits and vegetables by up to five times without the use of harmful chemicals. The company is committed to environmental sustainability, reducing agricultural waste, and supporting communities through charitable donations.

Gryphon Bio is a clinical stage company focused on developing novel blood tests for brain health, leveraging over 20 years of -omic research to identify brain-specific biomarkers in the blood. Their mission is to improve patient lives through innovative diagnostics for various central nervous system (CNS) diseases.